Bubs Australia (ASX: BUB): BUB's Rally Could Be Just Getting Started
Bubs Australia enters FY27 with permanent FDA approval, wider US distribution and strong American revenue growth. The company is expanding retail channels and rebuilding other markets, but higher freight costs, tariffs, negative EBITDA, and working-capital demands keep profitability and execution in focus.
Control Bionics (ASX: CBL) - This microcap's share price could explode higher from here!
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.
CSL Limited (ASX: CSL) – Structural Quality Re-Asserted
We believe CSL Limited (ASX: CSL) remains one of the highest-quality global healthcare franchises listed on the ASX, with FY25 marking a clear re-acceleration in earnings quality, cash flow conversion, and strategic clarity. While the share price has periodically struggled to reflect this underlying strength, we view CSL as misunderstood rather than mis-executing.
Atomo Diagnostics (ASX: AT1) uptrend is your friend!
Atomo Diagnostics (ASX: AT1) is showing a steady uptrend after a long quiet phase. Rising prices from recent lows, backed by stronger volume, suggest buyers are gradually absorbing supply. This persistent move higher points to improving sentiment and a technically supportive trend for now.
How much should we be scared of the recent gap down in CSL's (ASX: CSL) share price?
CSL Limited’s recent gap down reflects a sharp reset in market confidence rather than a collapse in its core business. The fall was driven by weaker-than-expected H1 FY26 results, plasma division margin pressure, policy headwinds in the US and China, a surprise CEO change, and earlier guidance cuts. While the stock is technically in a clear downtrend and deeply oversold, the long-term investment case now hinges on execution, margin recovery, and whether management can rebuild credibility.
Ansell Limited (ASX: ANN) – Margin Recovery and Attractive Long-Term Support Zone
We argue that despite cyclical and integration risks, Ansell’s improving margins and disciplined capital execution support a stable medium-term outlook. Technically and fundamentally, the A$28–30 range appears to represent a key support zone and a potentially attractive long-term entry level, provided earnings stability is maintained.